• 16953 Citations
1986 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

My primary clinical interest is in adult cardiovascular disease. My practice has focused on the management and treatment of patients with coronary artery disease. I am also interested in the diagnosis and management of arterial thrombosis. My research interests align with these clinical interests. My primary investigative focus is and has been on the mammalian plasminogen activator system and the role this system plays in cardiovascular disease. We apply a multidisciplinary approach in this effort, and utilize molecular and cellular approaches, as well as animal and human studies.

Certifications and Licenses

Cardiovascular Disease
Internal Medicine

Training Experience

1981Internship, Parkland Memorial Hospital
1983Residency, Parkland Memorial Hospital
1987Postdoctoral Fellowship, Harvard Medical School
1987Fellowship, Brigham & Women's Hospital

Education/Academic qualification

MD, University of Texas Southwestern Medical Center

… → 1980

Research interests

  • Aging
  • Cardiovascular Diseases
  • Gene Regulation
  • Stem Cells
  • Vascular Biology
  • Blood and Bleeding Disorders (anemia, clotting, etc.)

Fingerprint Dive into the research topics where Douglas E Vaughan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

  • Research Output

    Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA

    Campbell, P. T., VanWagner, L. B., Colangelo, L. A., Lewis, C. E., Henkel, A., Ajmera, V. H., Lloyd-Jones, D. M., Vaughan, D. E. & Khan, S. S., Jan 1 2020, (Accepted/In press) In : Liver International.

    Research output: Contribution to journalArticle

  • Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells

    Yahata, T., Ibrahim, A. A., Hirano, K. I., Muguruma, Y., Naka, K., Hozumi, K., Vaughan, D. E., Miyata, T. & Ando, K., May 1 2020, In : Haematologica. 105, 5

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    The socrates project for difficult diagnosis at northwestern medicine

    Singer, B. D., Goodwin, A. M., Patel, A. A. & Vaughan, D. E., Feb 2020, In : Journal of hospital medicine. 15, 2, p. 116-118 3 p.

    Research output: Contribution to journalReview article

    Open Access
    1 Scopus citations

    Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis

    Rai, R., Sun, T., Ramirez, V., Lux, E., Eren, M., Vaughan, D. E. & Ghosh, A. K., Apr 2019, In : Journal of Cellular and Molecular Medicine. 23, 4, p. 3026-3031 6 p.

    Research output: Contribution to journalArticle

    Open Access
  • Glycine supplementation extends lifespan of male and female mice

    Miller, R. A., Harrison, D. E., Astle, C. M., Bogue, M. A., Brind, J., Fernandez, E., Flurkey, K., Javors, M., Ladiges, W., Leeuwenburgh, C., Macchiarini, F., Nelson, J., Ryazanov, A. G., Snyder, J., Stearns, T. M., Vaughan, D. E. & Strong, R., Jun 2019, In : Aging Cell. 18, 3, e12953.

    Research output: Contribution to journalArticle

    Open Access
  • 5 Scopus citations